Stemtech Corporation (OTC:GNTW) Announces Appointment of John W. Meyer to Role of President and COO
Stemtech Corporation (OTC:GNTW) has appointed John W. Meyer as President and COO, also joining the Board of Directors. Meyer, who has been with Stemtech since 2006, will lead global operations and drive growth while reporting to CEO Charles S. Arnold. His extensive network marketing experience and operational oversight will be pivotal for the company's international expansion. CEO Arnold praised Meyer's dedication to sustainable growth and the value he brings to stakeholders, emphasizing his crucial role in the company's future.
- Appointment of an experienced leader, John W. Meyer, as President and COO, which could drive company growth.
- Meyer's long-standing experience in network marketing may enhance Stemtech's operational capabilities.
- Concerns about continuity and experience gaps if management changes lead to instability.
MIRAMAR, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (“Stemtech”) (OTC:GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has appointed John W. Meyer as President and COO, in addition to serving as a member of the Board of Directors.
Mr. Meyer joined Stemtech in 2006 and oversees all global operations. His responsibilities now include the role of President, where he will lead all aspects of Stemtech, reporting to CEO Charles S. Arnold and the Board of Directors. All functional departments and international operations are his responsibility to drive growth and expansion of the company.
Prior to joining Stemtech, John worked for other well-known network marketing companies, such as Shaklee and Arbonne International for over ten years. He also worked for over a decade in third party logistics on projects for Fortune 100 companies. He brought this experience and more to Stemtech, overseeing operations for the last fifteen years.
“In addition to his position of COO, we are proud to promote John to the role of President in recognition of his contribution and plans for leading Stemtech’s international growth going forward,” said CEO Charles S. Arnold. “John has been a mainstay of Stemtech since the inception of the company, and he is passionate about sharing both the benefits of our all natural, plant-based products, and the income earning business opportunity which Stemtech represents. He clearly has a comprehensive understanding of the business, and values our field of Independent Business Partners, customers and employees. It is a pleasure to work with John, and we believe that his deep commitment to sustainable growth for the company will be beneficial for all Stemtech stakeholders.”
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, DermaStem®, DermaStem Lift, OraStem® (Oral Health Care), and D-Fuze™. Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q filed July 13th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investors: Frank J. Pena, 908-675-0581, fpena@stemtech.com
FAQ
What is the significance of John W. Meyer's appointment at Stemtech (GNTW)?
How long has John W. Meyer been with Stemtech (GNTW)?
What are John W. Meyer's responsibilities as President and COO of Stemtech (GNTW)?
What is the background of John W. Meyer regarding network marketing?
